Ascelia Pharma AB (publ)

ACE · Nasdaq Stockholm · Healthcare

0.81SEK +1.4%last day

Price as of 2 October 2026

The price over the past year, with dividends: −76.2%

Performance

1 month

+28.6%

1 year

−76.2%

3 years, per year

−40.1%

5 years, per year

−51.8%

Largest fall, 3 years

−97.1%

Below the peak now

−98.7%

Volatility, 1 year

100.4%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

1.1

Dividend yield

0.0%

Return on equity

−66.9%

Net margin

–

Market value

11 m USD

Quality, value and trend

Where Ascelia Pharma stands against every Nordic stock today. 100 is best.

Quality72

Profitability and a sound balance sheet over time. Better than 72% of Nordic stocks.

Value12

The price measured against earnings, assets and cash flow. Better than 12% of Nordic stocks.

Trend25

The price development over the past year. Better than 25% of Nordic stocks.

Combined23

Quality, value and trend together. Better than 23% of Nordic stocks.

About Ascelia Pharma

Ascelia Pharma AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 10 employees.

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis